Αρχική World News Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined

Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined

A large comprehensive analysis of patient-specific alterations of the anaplastic lymphoma kinase (ALK) gene occurring in non-small cell lung cancer (NSCLC) reported at the European Lung Cancer Virtual Congress 2021 (25-27 March) provided additional insight into the landscape of ALK alterations that may guide treatment of NSCLC.

Aakash Desai from the Division of Oncology, MayoClinic in Rochester, MN, USA conducted a study describing the landscape of ALK alterations emphasising that the detection of ALK gene rearrangements in patients with newly diagnosed NSCLC remains critical. Recently, lorlatinib was found to be potent against all known single ALK resistance mutations including ALK G1202R in the CROWN study1. ALK alterations influence treatment decisions among the several other targeted mutations in lung cancer today.

Dr. Desai and co-investigators conducted a comprehensive analysis of patient-specific ALK alterations in NSCLC using the open-source American Association for Cancer Research (AACR) Project GENIE Cohort v8.1. Using cbioportal as a query database, they analysed 11,107 samples from 10,082 patients with lung adenocarcinoma to determine the prevalence of ALK fusions, mutations, and copy number alterations in NSCLC.

ALK fusion upstream partners and co-alterations identified

ALK alterations were detected in 584 (5%) of queried samples. These alterations comprised 354 (60.6%) missense mutations, 265 (45.4%) fusions, 51 (8.7%) truncating mutations, and 1 (0.17%) in-frame mutation.

The investigators excluded all alterations with mutations and copy number alterations that were of unknown significance and found that 284 (2%) of samples still had significant ALK alterations; of these 259 fusions and 25 missenses mutations were identified.

Regarding the 25 missense mutations, just 7 of 284 (2.46%) were mutations with G1202R protein change, 7 of 284 (2.46%) mutations with L1196M, and 4 of 284 with I1171N were identified; however, all of these were identified as oncogenic.

The most common ALK gene upstream partners of identified ALK fusions were EML4 (81.5%), KIF5B (1.5%), and SQSTM1 (1.1%). ALK fusions were found to be significantly co-altered with HSP90AB1 mutations (p = 2.51E-04), IDH2 mutations (p = 0.027), and NRG1 mutations (p = 0.024).


According to the authors, most ALK variants are described as variants of unknown significance (VUS), thus limiting the impact of precision oncology.

They found that ALK fusions occur in 2.6% of lung adenocarcinomas, with EML4 being the most common upstream partner. Meanwhile, G1202R mutations occur only among 0.07% of the ALK alterations.

The investigators also found that heat shock proteins and the Neuregulin-1 pathways may present additional opportunities for future combination targeted therapies in ALK-positive NSCLC. 

No external funding was disclosed.


  1. Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med 2020;383:2018-2029. DOI: 10.1056/NEJMoa2027187.


21P – Desai A, Mohammed T, Rakshit S, et al. The landscape of ALK alterations in non-small cell lung cancer. European Lung Cancer Virtual Congress 2021 (25-27 March).



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

10 Ways You Can Nurture A More Sustainable Garden

Sustainable gardening doesn’t have a firm, technical definition. It’s the concept of using sustainable gardening techniques that not only cause no harm to the...

Cancer Research UK spin-out gets US approval to trial unique T cell therapy

Cancer Research UK’s spin-out, GammaDelta Therapeutics (‘GammaDelta’), has been given approval from the US Food and Drug Administration (FDA) to trial its unique T-cell...

Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy

The ECOG-ACRIN EA1131 study hypothesised that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype triple-negative breast cancer...

Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit [ESMO Virtual Plenary Press Release]

VP6-2021 - IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk,...

Breaking News: Supreme Court Upholds the Affordable Care Act

It’s a great day for cancer survivors. The Supreme Court of the United States (SCOTUS) upheld the Affordable Care Act (ACA), commonly known as...

How Does CAR T-Cell Therapy Work in Treating Cancer?

Craig A. Portell, MD, is an Associate Professor of Medicine at the University of Virginia and a member of the UVA Cancer Center in...